Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus. It is active against bacteria, fungi, and higher eukaryotic cells by inhibiting protein synthesis. The mechanism of action involves binding to the ribosomal subunit (primarily 70S in prokaryotes and 80S in eukaryotes), where it interferes with translocation during protein elongation, causing mistranslation and ultimately halting cell growth. Hygromycin B is widely used as a selection agent in molecular biology for both prokaryotic and eukaryotic cells that express the hph resistance gene, which encodes a kinase that phosphorylates and inactivates the antibiotic. In veterinary medicine, it has been used as an anthelmintic (anti-worming) agent under the brand name Hygromix[1][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hygromycin B.